Mirum Pharmaceuticals, Inc. MIRM Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $254.38M+25.3% | $202.97M-27.0% | $278.12M+893% | $28M-10.6% | ||
| $86.64M+49.9% | $57.81M— | $0-100% | $123.72M-1.2% | ||
| $123.33M+57.5% | $78.29M+15.2% | $67.97M+183% | $23.99M+634% | ||
| $94.27M+9.6% | $86.04M+44.2% | $59.68M+221% | $18.61M+1,130% | ||
| $549.68M+39.9% | $392.79M+1.4% | $387.54M+104% | $190.23M+14.2% | ||
| $1.86M+63.5% | $1.14M+61.3% | $706K-22.8% | $914K-6.8% | ||
| $260.92M+4.4% | $249.82M-1.2% | $252.93M+329% | $58.95M+215% | ||
| $842.81M+25.7% | $670.75M+3.7% | $646.62M+83.2% | $352.91M+19.8% | ||
| $9.61M-34.2% | $14.62M+97.1% | $7.42M-14.7% | $8.69M-5.2% | ||
| $205.8M+62.6% | $126.55M+45.4% | $87.06M+34.5% | $64.73M+52.0% | ||
| $528.12M+18.6% | $445.11M+11.9% | $397.95M+88.7% | $210.87M+20.9% | ||
| 200M+3,999,900% | 5K0.0% | 5K+25.0% | 4K+33.3% | ||
| -$667.54M-3.6% | -$644.18M-15.8% | -$556.24M-41.6% | -$392.82M-52.8% | ||
| $314.69M+39.5% | $225.64M-9.3% | $248.67M+75.1% | $142.04M+18.2% | ||
| $842.81M+25.7% | $670.75M+3.7% | $646.62M+83.2% | $352.91M+19.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Mirum Pharmaceuticals, Inc.'s total assets?
- Mirum Pharmaceuticals, Inc. (MIRM) holds $890.9M in total assets, up 29.1% year over year.
- How much debt does Mirum Pharmaceuticals, Inc. have?
- Mirum Pharmaceuticals, Inc. carries $13.5M in total debt against $242.5M of shareholders' equity, a debt-to-equity ratio of 0.06.
- How much cash does Mirum Pharmaceuticals, Inc. have?
- Mirum Pharmaceuticals, Inc. holds $261.5M in cash and equivalents.
- Can Mirum Pharmaceuticals, Inc. cover its short-term obligations?
- Its current ratio is 2.09 — current assets exceed current liabilities.
- Where does Mirum Pharmaceuticals, Inc.'s balance sheet data come from?
- Every line is extracted from Mirum Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
